Viewray Inc (NASDAQ:VRAY) was the recipient of some unusual options trading on Tuesday. Stock investors acquired 2,022 put options on the company. This represents an increase of approximately 1,188% compared to the average daily volume of 157 put options.
Several institutional investors and hedge funds have recently modified their holdings of VRAY. Schwab Charles Investment Management Inc. acquired a new position in shares of Viewray in the 2nd quarter worth approximately $323,000. Rhumbline Advisers acquired a new position in shares of Viewray in the 2nd quarter worth approximately $193,000. Bank of New York Mellon Corp grew its position in shares of Viewray by 146.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 109,348 shares of the company’s stock worth $707,000 after acquiring an additional 64,976 shares in the last quarter. Alliancebernstein L.P. acquired a new position in shares of Viewray in the 2nd quarter worth approximately $248,000. Finally, White Pine Capital LLC acquired a new position in shares of Viewray in the 2nd quarter worth approximately $173,000. Institutional investors own 50.02% of the company’s stock.
Shares of Viewray (NASDAQ:VRAY) opened at $9.60 on Friday. Viewray has a 12 month low of $3.01 and a 12 month high of $10.64. The company has a current ratio of 1.59, a quick ratio of 1.20 and a debt-to-equity ratio of -1.67. The firm has a market capitalization of $683.54, a P/E ratio of -8.81 and a beta of 17.60.
A number of equities research analysts have weighed in on the company. BidaskClub lowered Viewray from a “buy” rating to a “hold” rating in a research note on Wednesday. Mizuho restated a “buy” rating and set a $12.00 price objective on shares of Viewray in a research note on Tuesday, January 9th. Cantor Fitzgerald set a $13.00 price objective on Viewray and gave the company a “buy” rating in a research note on Monday, January 8th. ValuEngine lowered Viewray from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, Northland Securities restated a “buy” rating and set a $10.00 price objective on shares of Viewray in a research note on Friday, November 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Viewray presently has an average rating of “Buy” and an average target price of $11.20.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.